Media
Lupin Receives Approval from U.S. FDA for Propranolol Hydrochloride Extended-Release Capsules USP
Mumbai, Baltimore, January 14, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Propranolol Hydrochloride Extended-Release Capsules USP, 60 mg, 80 mg, 120 mg, and 160 mg, to market a generic equivalent of Inderal® LA Extended- Release Capsules, 60 mg, 80 mg, 120 mg, and 160 mg, of ANI Pharmaceuticals, Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Propranolol Hydrochloride Extended-Release Capsules USP, 60 mg, 80 mg, 120 mg, and 160 mg are indicated for:
Hypertension
Propranolol Hydrochloride Extended-Release Capsules USP are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol Hydrochloride Extended-Release Capsules USP are not indicated in the management of hypertensive emergencies.
Angina Pectoris Due to Coronary Atherosclerosis
Propranolol Hydrochloride Extended-Release Capsules USP are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris.
Propranolol Hydrochloride Extended-Release Capsules USP are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use.
Hypertrophic Subaortic Stenosis
Propranolol Hydrochloride Extended-Release Capsules USP improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.
Propranolol Hydrochloride Extended-Release Capsules USP (RLD Inderal® LA) had estimated annual sales of USD 71 million in the U.S. (IQVIA MAT November 2023).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on:
Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: https://www.facebook.com/LupinWorld/
For further information or queries please contact –
Deputy General Manager – Corporate Communications
INDERAL® LA is a registered trademark of ANI Pharmaceuticals, Inc.
Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets
Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations
Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.06%
CloseSearch Product
